International Journal of Nephrology and Renovascular Disease
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Complete response of a metastatic gastroesophageal adenocarcinoma on irinotecan-based chemotherapy in a dialysis patient
(4199) Total Article Views
Authors: J Verwimp, F Geurs, S Ponette, et al
Published Date May 2010
Volume 2010:3 Pages 61 - 64
J Verwimp1, F Geurs1, S Ponette2, J Ponette2, J Martens3, K Bulté2
1Department of Medical Oncology, 2Department of Gastroenterology, 3Department of Nephrology, Regionaal Ziekenhuis Sint-Maria, Ziekenhuislaan, Halle, Belgium
Abstract: We present the first case report of a complete response of metastatic gastroesophageal cancer in a chronic hemodialysis patient with irinotecan-based chemotherapy. An elderly dialysis patient presented with diffuse liver metastases by a gastroesophageal adenocarcinoma. He received combination chemotherapy with 5 fluorouracil and irinotecan. After six months of chemotherapy, liver scans show complete remission. The principles, practice, and experience of chemotherapy with irinotecan during dialysis are discussed.
Keywords: gastroesophageal cancer, irinotecan, chemotherapy, dialysis
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Other articles by Dr Filip Geurs
Readers of this article also read:
- MLA'14 -
May 16–21, 2014
- Functional evaluation of the urinary tract by duplex Doppler ultrasonography in patients with acute renal colic
- Potential renovascular hypertension, space missions, and the role of magnesium
- Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs
- Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?